Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the U.S.

Posted On: 2019-10-14 09:42:03

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that one of its wholly-owned subsidiaries has commercialized CEQUA (cyclosporine ophthalmic solution) 0.09% in the U.S. CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the U.S. Food and Drug Administration (FDA), is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye), an inflammatory disease that afflicts more than 16 million people in the U.S.1 CEQUA is the first and only FDA-approved cyclosporine treatment delivered with nanomicellar (NCELL™) technology, which helps to improve the bioavailability and physicochemical stability of cyclosporine, resulting in improved ocular tissue penetration.

"The U.S. launch of CEQUA, the third product in our growing ophthalmic portfolio, marks the availability of a truly innovative treatment option for patients with dry eye disease - an area with a high unmet medical need," said Abhay Gandhi, CEO North America, Sun Pharma. "As a higher concentration cyclosporine product than what is currently commercially available, delivered with NCELL technology, CEQUA continues to demonstrate our leadership in creating novel formulations of proven medications."

This announcement follows the recent publication of results from a multicenter, randomized, doublemasked, vehicle-controlled Phase 3 confirmatory study in which 744 patients with dry eye were treated either with CEQUA or its vehicle. After 12 weeks of treatment, as compared to vehicle, CEQUA showed a statistically significant improvement in the primary endpoint, percentage of patients with an increase of at least 10 mm in Schirmer's score (a measurement of tear production) from baseline (16.6% vs. 9.2%; p<0.01). Additionally, CEQUA was associated with statistically significant improvements in the key secondary endpoints, with improvements in both corneal and conjunctival staining, compared to vehicle; improvement in total corneal staining was evident as early as one month following treatment, with 65% of eyes having completely clear central cornea after 12 weeks (vs 56.9% for vehicle; p=0.0022). Adverse events (AEs) reported in the trial were mostly mild in severity. The most commonly reported ocular AE was instillation site pain (24.2% in the CEQUA group, vs. 4.3% for vehicle); of the 24.2% of patients who reported instillation site pain in the CEQUA group, most of them reported the pain as being mild (20.7%), 3.0% reported it as moderate, and 0.5% reported it as severe.

"CEQUA is an important addition to the treatment armamentarium for keratoconjunctivitis sicca, a complex condition that is not conducive to a one-dimensional therapeutic approach," commented Joseph Tauber, M.D., founder, Tauber Eye Center in Kansas City, MO. "The availability of CEQUA will enable eye care professionals to further tailor dry eye treatment to individual patients' needs."

Paul Karpecki, O.D., FAAO, director of cornea services at the Kentucky Eye Institute in Lexington, KY, added, "Keratoconjunctivitis sicca causes symptoms of burning, stinging, itching, grittiness, and dryness, underscoring the need for tolerable drug therapy with a fast onset of action. The CEQUA clinical study results strengthen the rationale for using this product as a means to penetrate the tear film and improve drug delivery of cyclosporine into the eye."

Sun Pharma is also introducing CEQUA SUPPORT™ Specialty Pharmacy, a program designed to enable commercially insured patients to easily obtain CEQUA. Once a patient's prescription is submitted, CEQUA SUPPORT will provide several important services including insurance plan benefits verification, prior authorization support, and appeals assistance. This program is structured to minimize out-of-pocket cost and provides free home delivery.

Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.386.3 as compared to the previous close of Rs. 386.95. The total number of shares traded during the day was 213376 in over 2903 trades.

The stock hit an intraday high of Rs. 388.9 and intraday low of 381.6. The net turnover during the day was Rs. 82096624.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Aurobindo Pharma Ltd's Unit IV gets 14 observations from US FDA

Veto Switchgears and Cables reports Q2 FY20 results

Vedanta's Aluminium & Power Business wins Jamkhani Coal Block

Oracle Financial Services Software Reports Q2 Fiscal Year 2020

UFlex Closes Q2 of FY19-20 with EBITDA of 279 cr

Trigyn Technologies Ltd results - Highlights for Q2 & H1 FY2019-20

Fermenta Biotech Ltd board approves interim dividend of Rs. 5 for 2019-20

Pidilite Industries reports Q2 FY20 earnings

Navneet Education Limited Board approves interim dividend of Rs. for 2019-20

Singer India Limited announces Q2, H1 FY20 results

Saksoft Ltd H1FY20 Revenue at Rs. 178.39 Crs

New India Assurance Company Ltd reports Rs. 530 crores PAT in Q2

Ashoka Buildcon Q2FY20 EPC Revenue at Rs. 862Crores

Mishra Dhatu Nigam Ltd secures order of Rs. 106 crores

Nilkamal Ltd Board approves interim dividend of Rs. 5 for 2019-20

Snowman Logistics Ltd announces Q2 FY20 results

Mindteck Reports Financial Results for the Quarter Ended September 30, 2019

Cardinal Health Partners with TCS to Transform its IT Operating Model

SpiceJet posts a loss in Q2

ITD Cementation India Ltd Q2 consolidated net profit at Rs. 21.68 crores

Fine Organic Industries Ltd reports consolidated PAT of Rs. 57.03 crores in Q2

Hindustan Tin Works Ltd Q2 net profit jumps to Rs. 4.22 crores

Nandan Denim Ltd Q2 PAT at Rs. 2.20 crores

Amines & Plasticizers Ltd Q2 consolidated net profit soars to Rs. 6.85 crores

Galaxy Surfactants Ltd Q2 FY20 consolidated PAT climbs to Rs. 67.07 crores

Munjal Auto Industries Ltd reports consolidated net profit of Rs. 1.38 crore in Q2

A K Capital Services Ltd consolidated Q2 net profit at Rs. 10.47 crores

Trigyn Technologies Ltd posts consolidated PAT of Rs. 14.63 crores in Q2

Power Mech Projects Ltd Q2 FY20 consolidated net profit at Rs. 35.10 crores

SPL Industries Ltd Q2 net profit rises to Rs. 12.02 crores

Apex Frozen Foods Ltd Q2 net profit at Rs. 21.92 crores

KSE Ltd reports PAT of Rs. 4 crores in Q2

SEAMEC Ltd consolidated Q2 net profit at Rs. 26.82 crores

Nilkamal Ltd consolidated Q2 PAT at Rs. 49.01 crores

Gulshan Polyols Ltd reports net profit of Rs. 5.73 crores in Q2

Aarti Industries Ltd Q2 consolidated PAT at Rs. 147.56 crores

Permanent Magnets Ltd Q2 PAT higher at Rs. 3.71 crores

TD Power Systems Ltd reports consolidated PAT at Rs. 5.74 crores

CMI Ltd reports net profit of Rs. 1.09 crore in Q2

Cosmo Films Ltd Q2 consolidated PAT up at Rs. 28.70 crores

BATA India Ltd consolidated Q2 net profit at Rs. 71.30 crores

Finolex Cables Ltd posts consolidated PAT of Rs. 126.84 crores in Q2 FY20

Shreyans Industries Ltd reports net profit of Rs. 7.81 crores

Haryana Leather Chemicals Ltd posts PAT of Rs. 0.51 crore in Q2

Wanbury Ltd Q2 net profit at Rs. 5.02 crores

Saregama India Ltd consolidated Q2 net profit up at Rs. 19.26 crores

Himadri Speciality Chemical Ltd reports consolidated PAT at Rs. 45.16 crores

Thermax Ltd reports consolidated PAT declines to Rs. 25.70 crores

Lux Industries Ltd consolidated Q2 PAT at Rs. 40.59 crores

Indian Hume Pipe Company Ltd Q2 PAT slides to Rs. 14.20 crores







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019